Orforglipron
Orforglipron (LY3502970)
Also known as: LY3502970, Oral GLP-1
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
Eli Lilly's oral GLP-1 agonist — a daily pill, not an injection. Phase 2 showed 14.7% weight loss, potentially making GLP-1 therapy as simple as taking a tablet.
Quick Facts
Investigational compound developed by Eli Lilly. Currently in Phase 3 clinical trials (ATTAIN program) for obesity and type 2 diabetes. Not yet approved by any regulatory agency.
Overview
Orforglipron (LY3502970) is a non-peptide, orally bioavailable GLP-1 receptor agonist developed by Eli Lilly. It represents a potential paradigm shift in metabolic medicine: delivering the benefits of GLP-1 receptor activation — appetite suppression, glycemic control, and weight loss — through a daily pill rather than a weekly injection.
Critically, orforglipron is NOT a peptide. It is a small molecule that mimics the action of GLP-1 at its receptor. This distinction matters because peptide-based GLP-1 agonists like semaglutide are destroyed by stomach acid and must be injected (or require complex formulation for oral delivery, as with oral semaglutide/Rybelsus). Orforglipron sidesteps this entirely through its non-peptide structure.
Eli Lilly is running the ATTAIN clinical trial program, which includes Phase 3 studies in both obesity and type 2 diabetes. Phase 2 data showed weight loss of up to 14.7% over 36 weeks, placing it in a competitive range with injectable GLP-1 therapies. If approved, orforglipron could dramatically expand access to GLP-1 therapy by removing the injection barrier.
Mechanism of Action
Orforglipron is a full agonist at the glucagon-like peptide-1 (GLP-1) receptor, the same target as semaglutide and liraglutide. However, it achieves this through a non-peptide small molecule structure rather than a modified peptide chain.
GLP-1 receptor activation produces several downstream effects: stimulation of glucose-dependent insulin secretion from pancreatic beta cells, suppression of inappropriate glucagon release, delayed gastric emptying, and central appetite suppression through hypothalamic signaling.
The appetite suppression mechanism involves GLP-1 receptor activation in the brainstem (area postrema and nucleus tractus solitarius) and hypothalamus, reducing hunger signaling and increasing satiety. This is the primary driver of weight loss.
Orforglipron has a half-life of approximately 25–65 hours, supporting once-daily oral dosing. Its small molecule structure provides inherent resistance to proteolytic degradation in the GI tract — the fundamental limitation of peptide-based oral GLP-1 agents. This means it does not require the fasting conditions or absorption enhancers needed for oral semaglutide (Rybelsus).
Research Summary
Phase 2 clinical trial data for orforglipron were published in the New England Journal of Medicine in 2023. In a 36-week, dose-ranging study of adults with obesity (n=272), orforglipron at the highest dose (36 mg daily) produced a mean weight loss of 14.7% from baseline. Lower doses (12 mg, 24 mg) produced 9.4% and 12.6% weight loss respectively.
In a parallel Phase 2 study in type 2 diabetes (n=383), orforglipron reduced HbA1c by up to 2.1 percentage points at 26 weeks, with concurrent weight loss of up to 7.9%. These glucose-lowering effects are comparable to injectable GLP-1 agonists.
The ATTAIN Phase 3 program launched in 2023 and includes trials in obesity (ATTAIN-1), type 2 diabetes (ATTAIN-2 through ATTAIN-4), and cardiovascular outcomes. Results are expected between 2025 and 2027.
The GI side effect profile in Phase 2 was consistent with the GLP-1 class: nausea, vomiting, and diarrhea were the most common adverse events, occurring primarily during dose escalation. Discontinuation rates due to GI side effects were 10–17% depending on dose.
Competitive landscape: Orforglipron competes with Pfizer's danuglipron (another oral GLP-1) and Roche's oral candidates. It also competes indirectly with Eli Lilly's own tirzepatide (injectable dual GIP/GLP-1 agonist).
Key References
Orforglipron (LY3502970), a novel oral non-peptide GLP-1 receptor agonist, for the treatment of type 2 diabetes
Frias JP, et al. · New England Journal of Medicine (2023) · 10.1056/NEJMoa2302392
Phase 2 trial in type 2 diabetes showing orforglipron reduced HbA1c by up to 2.1% and body weight by up to 7.9% over 26 weeks, with a GI side effect profile consistent with the GLP-1 class.
Orforglipron for the treatment of obesity
Wharton S, et al. · New England Journal of Medicine (2023) · 10.1056/NEJMoa2302305
Phase 2 trial in obesity demonstrating up to 14.7% weight loss over 36 weeks with daily oral orforglipron, supporting advancement to Phase 3 trials.
Discovery of orforglipron (LY3502970): a novel oral non-peptide GLP-1 receptor agonist
Kawai T, et al. · Journal of Medicinal Chemistry (2022) · 10.1021/acs.jmedchem.2c00584
Describes the medicinal chemistry and structure-activity relationship studies that led to the discovery of orforglipron as an orally bioavailable, potent GLP-1 receptor agonist.
GLP-1 receptor agonists in the treatment of obesity: current evidence and future directions
Drucker DJ. · Nature Reviews Endocrinology (2024) · 10.1038/s41574-024-00958-y
Comprehensive review placing oral GLP-1 agonists like orforglipron in the context of the broader GLP-1 therapeutic landscape, including comparisons with injectable agents.
Protocols
Phase 2 dose escalation (obesity)
Dose escalation is critical: patients start at 3 mg daily for 2 weeks, then escalate by 3 mg every 2 weeks until reaching the target dose. This gradual escalation significantly reduces GI side effects. Taken with or without food — no fasting requirement.
Phase 2 dose escalation (type 2 diabetes)
Same dose escalation approach. The 45 mg dose was tested in the diabetes trial. Glycemic improvements were seen across all dose levels with dose-dependent weight loss.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Nausea The most frequently reported side effect (30–50% of participants). Most common during dose escalation and tends to diminish over time. |
| common | Vomiting Reported in 15–25% of participants depending on dose. Gradual dose escalation helps mitigate severity. |
| common | Diarrhea Reported in 15–20% of participants. Typically mild to moderate and transient. |
| common | Decreased appetite A therapeutic effect for obesity treatment but classified as a side effect in clinical reporting. |
| uncommon | Constipation Less common than diarrhea. Related to delayed gastric emptying. |
Contraindications
- —Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 class warning based on rodent thyroid C-cell tumor data
- —History of multiple endocrine neoplasia syndrome type 2 (MEN 2)
- —Known hypersensitivity to orforglipron or any excipients
- —Pregnancy or breastfeeding (insufficient safety data)
- —History of pancreatitis (GLP-1 class precaution)
Interactions
- —Insulin and sulfonylureas: increased risk of hypoglycemia when combined. Dose adjustment of insulin or sulfonylurea may be necessary.
- —Oral contraceptives: delayed gastric emptying may affect absorption. Use backup contraception during dose escalation.
- —Oral medications with narrow therapeutic index: delayed gastric emptying may alter absorption kinetics. Monitor drug levels.
Reconstitution & Storage
Related Peptides
Orforglipron is not used in combination with other GLP-1 agonists. It is positioned as a potential oral alternative to injectable GLP-1 therapies like semaglutide and tirzepatide. For patients who cannot tolerate injections, orforglipron may eventually provide equivalent metabolic benefits in pill form.